Nearly 35,000 Americans die each year due to opioid overdose, around the same number that die in car crashes. Despite attempts from doctors and policy makers to quell this epidemic, the rate of overdose death continues to rise. Nora Volkow, Director of the National Institute on Drug Abuse (NIDA), and Francis Collins, Director of the NIH, announced earlier this year in the New England Journal of Medicine that the NIH is working with industry and regulatory partners to set up a public–private partnership (PPP) that will accelerate the discovery and development of new non-addictive analgesics, overdose-reversal agents and anti-addiction treatments in an attempt to stem the tide. Volkow spoke with Asher Mullard about her ambitious goal to halve the development timeline for these types of drug.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 /Â 30Â days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Nora Volkow. Nat Rev Drug Discov 16, 746–747 (2017). https://doi.org/10.1038/nrd.2017.215
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.215
